| Autor: |
Solis-Paredes JM; Clinical Research Branch, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico., Montoya-Estrada A; Coordination of Gynecological and Perinatal Endocrinology, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico., Cruz-Rico A; Coordination of Gynecological and Perinatal Endocrinology, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico., Reyes-Muñoz E; Coordination of Gynecological and Perinatal Endocrinology, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico., Perez-Duran J; Clinical Research Branch, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico., Espino Y Sosa S; Clinical Research Branch, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico.; ABC Medical Center, Medical Association, Mexico City 05300, Mexico., Garcia-Salgado VR; Clinical Research Branch, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico., Sevilla-Montoya R; Clinical Research Branch, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico., Martinez-Portilla RJ; Clinical Research Branch, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico.; ABC Medical Center, Medical Association, Mexico City 05300, Mexico., Estrada-Gutierrez G; Clinical Research Branch, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico., Gomez-Ruiz JA; Maternal-Fetal Medicine Department, Hospital General de Mexico 'Dr. Eduardo Liceaga', Mexico City 06720, Mexico., Mateu-Rogell P; Clinical Research Branch, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico., Villafan-Bernal JR; Laboratory of Immunogenomics and Metabolic Diseases, Instituto Nacional de Medicina Genomica, Mexico City 14610, Mexico., Rojas-Zepeda L; Maternal Fetal Medicine Department, Instituto Materno Infantil del Estado de México, Toluca 50170, Mexico., Del Carmen Perez-Garcia M; Obstetrics & Gynecology Resident, Instituto Nacional de Perinatología, Mexico City 11000, Mexico., Torres-Torres J; Clinical Research Branch, Instituto Nacional de Perinatologia, Mexico City 11000, Mexico.; ABC Medical Center, Medical Association, Mexico City 05300, Mexico.; Maternal-Fetal Medicine Department, Hospital General de Mexico 'Dr. Eduardo Liceaga', Mexico City 06720, Mexico. |
| Abstrakt: |
Oxidative stress (OS) induced by SARS-CoV-2 infection may play an important role in COVID-19 complications. However, information on oxidative damage in pregnant women with COVID-19 is limited. Objective: We aimed to compare lipid and protein oxidative damage and total antioxidant capacity (TAC) between pregnant women with severe and non-severe COVID-19. Methods: We studied a consecutive prospective cohort of patients admitted to the obstetrics emergency department. All women positive for SARS-CoV-2 infection by reverse transcription-polymerase chain reaction (RT-qPCR) were included. Clinical data were collected and blood samples were obtained at hospital admission. Plasma OS markers, malondialdehyde (MDA), carbonylated proteins (CP), and TAC; angiogenic markers, fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF); and renin-angiotensin system (RAS) markers, angiotensin-converting enzyme 2 (ACE-2) and angiotensin-II (ANG-II) were measured. Correlation between OS, angiogenic, and RAS was evaluated. Results: In total, 57 pregnant women with COVID-19 were included, 17 (28.9%) of which had severe COVID-19; there were 3 (5.30%) maternal deaths. Pregnant women with severe COVID-19 had higher levels of carbonylated proteins (5782 pmol vs. 6651 pmol; p = 0.024) and total antioxidant capacity (40.1 pmol vs. 56.1 pmol; p = 0.001) than women with non-severe COVID-19. TAC was negatively correlated with ANG-II (p < 0.0001) and MDA levels (p < 0.0001) and positively with the sFlt-1/PlGF ratio (p = 0.027). Conclusions: In pregnant women, severe COVID-19 is associated with an increase in protein oxidative damage and total antioxidant capacity as a possible counterregulatory mechanism. |
